LNAI — Lunai Bioworks Inc.
NASDAQ · Healthcare · Biotechnology
$2.14
-$0.01 (-0.47%)
Lunai Bioworks Inc. (LNAI) is a biotechnology company listed on NASDAQ. It is led by David H. Weinstein, based in 2080 Century Park East, Los Angeles, CA, United States, 90067, with about 29 employees. Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Net income was $2.8M. LNAI currently screens at market cap $12.4M.
Use this LNAI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LNAI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LNAI SEC filings page. Lician reads the product cache first so this HTML stays unique to Lunai Bioworks Inc. even when a live quote feed is slow.
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
LNAI Key Statistics
Market Cap
$12.35M
Volume
6,068
Previous Close
$2.13
Day Range
$2.13 – $2.27
P/B Ratio
0.48
EPS
-$1.08
Revenue
$0.00
Net Income
-$178.01M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
29
LNAI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$178.01M | -$88.43M | -$39.68M | -$113.43M |
| EPS (Diluted) | -$1.08 | -$0.91 | -$0.71 | -$2.16 |
Total Assets
$8.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$92.70K
Operating Cash Flow
-$7.87M
Free Cash Flow
$0.00
Lunai Bioworks Inc. Company Information
- CEO & Director
- David H. Weinstein
- Headquarters
- 2080 Century Park East, Los Angeles, CA, United States, 90067
- Website
- www.lunaibioworks.com
- Phone
- 305 918 1980
- IPO / Founded
- 2015-02-02
- Sector
- Healthcare
- Industry
- Biotechnology